Editas Medicine reported positive first-quarter 2026 results, highlighting progress on EDIT-401, a gene-editing therapy aimed at treating hyperlipidemia by significantly reducing LDL cholesterol and other cardiovascular risk factors in preclinical studies. The company plans to start first-in-human trials for EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia later this year, with early proof-of-concept data expected by year-end 2026. Financially, Editas reduced its net loss compared to the previous year and maintains sufficient cash to fund operations into late 2027. The company also confirmed a favorable patent decision supporting its CRISPR technology rights. Upcoming presentations will share new preclinical data at major scientific conferences.
Perplexity AI CEO Aravind Srinivas shared lessons from Nvidia's Jensen Huang and Tesla's Elon Musk, highlighting Huang's mindset of running Nvidia as if it could fail within 30 days despite its $5 trillion valuation and advanced technology. Srinivas ...
Meta Platforms introduced an AI-powered feature called "AI Mode" within Facebook Search, which uses Meta's AI model Muse Spark to provide answers from public content rather than traditional search results. This innovation could generate over $10 bill...
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
